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Despite the concern of replacement disease, notably 
by serotype 19A after 7-valent conjugate vaccine (PCV7) 
use, serotype 19A was increasingly recognized in Korean 
children before the introduction of PCV7. To understand the 
dynamics of serogroup 19 prevalence from 1991–2006, we 
serotyped 538 pediatric pneumococcal isolates. Serogroup 
19 isolates (n = 126) were characterized by antimicrobial 
drug susceptibility, presence of mefA/ermB, and multilocus 
sequence typing. Overall, the proportion of serotype 19A 
isolates increased but serotype 19F decreased. Among 
children <5 years of age, the proportion of serotype 19A 
isolates in invasive pneumococcal disease increased from 
0% in 1991–1994 to 8%–10% in 1995–2000, reached 26% 
in 2001–2003, and remained at 20% in 2004–2006 when 
vaccine coverage did not exceed 25% (p = 0.005 for trend). 
This study demonstrates that the expansion of multidrug-re-
sistant ST320 was responsible for the increase in serotype 
19A before PCV7 use. 
S
treptococcus pneumoniae is a major cause of invasive 
infections in young infants and children. Among >90 
serotypes, only a limited number account for pneumococ-
cal diseases. Serotype incidence can vary by patient age, 
geographic region, and time of surveillance. Since the intro-
duction of 7-valent conjugate vaccine (PCV7) in the United 
States, a decrease in the incidence of invasive pneumococ-
cal disease (IPD) caused by vaccine serotypes has been 
observed in pediatric and nonpediatric age groups (1,2). 
However, the incidence of IPD caused by nonvaccine sero-
types (including serotype 19A) increased 1.5-fold in 2002 
compared to that in 1999 (2,3). To date, replacement for 
IPD has been observed for serotypes 3, 15, 19A, 22F, 33F, 
and 35, with the increase in 19A being the most prevalent. 
(2–7). Recently, Singleton et al. reported that serotype 19A 
was responsible for 28.3% of IPD in rural Alaska Native 
children <2 years of age during 2004–2006 (8). In addition, 
recent studies from Massachusetts and Texas showed that 
a multidrug-resistant sequence type of serotype 19A has 
emerged as an important cause of IPD (9,10).
The direct effects of PCV7 in serotype distribution 
changes and genetic structures of pneumococcal isolates 
are not clear. However, capsular switching of vaccine se-
rotypes under selective pressure by PCV7 is one of the 
mechanisms underlying the expansion of serotype 19A 
(4,11–13).
As part of this surveillance implemented in a tertiary 
referral center in South Korea, all pneumococcal isolates 
obtained from sterile body ﬂ  uids and from various clini-
cal specimens were subjected to serotype and antimicrobial 
drug susceptibility pattern determinations (14). Surveil-
lance since 1991 shows that serotype 19A isolates were 
increasingly recognized among clinical isolates before 
PCV7 was introduced in South Korea in November 2003. 
We describe S. pneumoniae serotype distribution changes 
in Korean children during 1991–2006 with an emphasis on 
serogroup 19.
Methods
Patients and Pneumococcal Isolates 
Hospital-wide surveillance was continued to monitor 
pneumococcal diseases as a part of routine clinical care at 
Seoul National University Children’s Hospital from 1991 
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through 2006. Only initial isolates were included in the 
study; repeated isolates from the same patient were exclud-
ed. Isolates were classiﬁ  ed as invasive (e.g., blood, pleu-
ral ﬂ  uid, cerebrospinal ﬂ  uid, joint ﬂ  uid) and noninvasive 
(pharynx, middle ear ﬂ  uid, sputum). Methods of surveil-
lance and of obtaining blood cultures did not change during 
the study period. 
Analysis of Serotype Distributions and Classiﬁ  cations 
All isolates were serotyped by the Quellung reaction 
using antiserum (Statens Serum Institute, Copenhagen, 
Denmark). The study period was divided into ﬁ  ve 3- or 4- 
year-periods: 1991–1994 (period 1), 1995–1997 (period 2), 
1998–2000 (period 3), 2001–2003 (period 4), and 2004–
2006 (period 5). The PCV7 serotypes were 4, 6B, 9V, 14, 
18C, 19F, and 23F. Serotypes considered to be PCV7 re-
lated included those not directly targeted by PCV7 but of 
the same serogroups (6A, 9A, 9N, 18B, 18F, and 23A); se-
rotype 19A was analyzed separately. Non-PCV7 serotypes 
included all other serotypes.
Multilocus Squence Typing Analysis
Multilocus sequence typing (MLST) was performed 
on all serotype 19A isolates (n = 58) and serotype 19F iso-
lates (n = 68) obtained from children <5 years of age (15–
17). New alleles were veriﬁ  ed by resequencing gene frag-
ments of both strands. When sequence types (STs) that had 
not been associated with a particular serotype in the past 
were identiﬁ   ed, serotyping and sequencing typing were 
conﬁ  rmed by repeating the reactions. STs were divided 
into sets using eBURST software (Imperial College, Lon-
don, UK) (18), which is available at the MLST database. 
eBURST sets meet the requirement that all STs must be 
single-locus variants (SLVs) of at least 1 other ST within 
the group. Founder STs were deﬁ  ned as described previ-
ously (18). Clonal complexes (CCs) consisted of eBURST 
sets or eBURST sets plus related STs that shared 5 of 7 
allelic identities with most other STs included within an 
eBURST set. 
Antimicrobial Drug Susceptibility Testing and Detec-
tion of ermB/mefA Genes 
MICs of serogroup 19 were determined for 6 antimi-
crobial drugs (penicillin, cefotaxime, chloramphenicol, tet-
racycline, clindamycin, and erythromycin) by E-test (AB 
Biodisk, Solna, Sweden) (19). Susceptibilities to vancomy-
cin and trimethoprim-sulfamethoxazole were determined 
by disk diffusion test. Multidrug resistance was deﬁ  ned as 
nonsusceptibility to >3 antimicrobial drug classes. The mefA 
and ermB genes were detected by PCR using the primers 
mefA (forward, 5′-AGT ATC ATT AAT CAC TAG TGC-
3′; reverse, 5′-TTC TTC TGG TAC TAA AAG TGG-3′) 
and ermB (forward, 5′-GAA AAG GTA CTC AAC CAA 
ATA-3′; reverse, 5′-GTA ACG GTA CTT AAA TTG TTT 
AC-3′) (20). PCRs were performed with 35 ampliﬁ  cation 
cycles: 30 s at 94°C, 30 s at 50°C, and 1 min 30 s at 72°C, 
followed by a ﬁ  nal extension at 72°C for 10 min.
Statistical Analysis
Statistical analysis was performed by using SPSS soft-
ware version 13.0 (SPSS, Chicago, IL, USA). Serotype 
proportion in each period was compared using the χ2 or 
Fisher exact test, as appropriate. The Mantel-Haenszel χ2 
test was used for trend analysis.
Results
Changes in Serotype Distributions 
From 1991 through 2006, 538 strains of S. pneumoniae 
were obtained from various clinical specimens. Of these, 
158 (29%) were from invasive isolates; 124 blood, 15 cere-
brospinal ﬂ  uid, 6 pleural ﬂ  uid, 5 ascites, and 8 other sterile 
deep-seated tissues (e.g., bone and joint ﬂ  uid). The remain-
ing 380 (71%) were from noninvasive isolates; 110 (pha-
ryngeal swab), 91 (transtracheal aspirate), 81 (sputum), 69 
(middle ear ﬂ  uid), 15 (urine), and 14 (open pus). 
The most common serotypes were 19F (113, 21%), 
23F (96, 17.8%), 19A (58, 10.8%), 6B (50, 9.3%), 6A (43, 
8%), 14 (40, 7.4%), and 9V (24, 4.5%); these 7 serotypes 
accounted for 79% of the total isolates. Overall, PCV7 se-
rotypes accounted for 64.1% of total isolates and 62.7% of 
invasive isolates. Table 1 shows the serotype distributions 
of invasive and noninvasive isolates by age group. For in-
vasive isolates, PCV7 serotype coverage was 67% among 
children <60 months of age and 47% among children >60 
months (Table 1). During 2001–2003, just before PCV7 
was introduced in South Korea, overall PCV7 coverage 
rates for PCV7 serotypes and PCV7-related serotypes were 
54% and 10% among the 138 invasive isolates and 57% 
and 13% among the 380 noninvasive isolates. The propor-
tion of serotype 19A isolates increased from 0% (0/40) dur-
ing 1991–1994 to 18% (7/39) during 2001–2003 among the 
138 invasive isolates. Similarly, from 1995–1997 to 1998–
2000, the proportion of serotype 19A isolates increased 
from 3% (1/33) to 17% (14/81) among noninvasive isolates 
(Figure 1).
Among the 107 invasive isolates from children <5 years 
of age (Figure 2), serotype 19F decreased from 31% (8/26) 
in period 1 to 13% (3/24) in period 2 and to 5% (1/20) in 
periods 3 and 4 (p = 0.008 for trend). The proportion of 
19A increased from 0% (0/26) in period 1 to 8% (2/24) in 
period 2 and reached 26% (7/27) in period 4 (p = 0.005 for 
trend). There were no signiﬁ  cant trends for the remaining 
serotypes: 23F (p = 0.58), 14 (p = 0.28), 9V (p = 0.23), 6A 
(p = 0.38), and 6B (p = 0.23). During period 5, after vac-
cine introduction, the proportion of 19A isolates was 20% 
276  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 2, February 2008Streptococcus pneumoniae Serotype 19A in Children
(2/10). During 2001–2003, 19A was the most common se-
rotype among IPD isolates from South Korean children <5 
years of age. During 2004–2006, the postvaccine period, 
when PCV7 uptake reached ≈20%–25% of South Korean 
children <2 years of age (21), the distribution of serotypes 
was unaltered compared with distribution during the pre-
vaccine 2001–2003 period. There was no major change in 
antimicrobial drug treatment policy or pressure to use an-
timicrobial drugs in the local pediatric practice during the 
study period.
MLST Analysis of Serogroup 19 
MLST analysis showed 4 STs among the 58 serotype 
19A isolates: ST320 (52 isolates), ST 1374 (4), ST1451 
(1), and ST2394 (1). Eighteen STs were found among the 
68 serotype 19F isolates: ST271 (14 isolates), ST320 (6), 
ST236 (14), ST283 (7), ST1464 (10), ST2395 (3), ST2695 
(3), and 1 isolate each of ST1203, ST1412, ST1417, 
ST2396, ST2397, ST2398, ST2399, ST2694, ST2696, 
ST2697, and ST2698. Through the course of this study, 
11 new STs (ST2394-ST2399 and ST2694-ST2698) were 
identiﬁ  ed among the serogroup 19 isolates, and 8 of these 
were SLVs or double-locus variants of ST271. 
According to eBURST analysis, 1 major CC (CC271) 
accounted for most of the isolates (n = 116, 92% of se-
rotypes 19A and 19F). CC271 comprised 16 STs, where 
ST271 was predicted as the founder, and ST320 was the 
predominant allelic proﬁ  le. The 5 ST lineages that were 
unrelated to CC271 were nonlinked singlets (ST1203, 
ST1374, ST2394, ST2395, and ST2399) (Figure 3).
ST320 was the only ST found among serotypes 19A 
and 19F; ST320 was the most common ST (n = 52, 90% 
of total 19A isolates) among serotype 19A. ST320 was ob-
served in only 9% (n = 6) of serotype 19F isolates. The 
genetic structure of serotype 19A comprised primarily 
ST1374 during periods 1 and 2 (1991–1997), but ST1374 
isolates were not recovered after 2001. In contrast, ST320 
was the most common sequence type from 1998, and all 
19A isolates from 2002–2006 were of ST320. The numbers 
of 19A isolates increased consistently from 1996 through 
2003, which suggests that single clonal expansion of ST320 
was responsible for the increase of serotype 19A isolates 
during this period (Figure 4). 
Unlike serotype 19A, serotype 19F comprises diverse 
STs grouped within CC271 (16 STs) and 5 different singlets. 
All STs, except ST1203, were associated with multidrug-
resistant mef/erm-containing isolates. The distributions of 
predominant STs among serotype 19F isolates varied dur-
ing each study period (Figure 4). For example, ST2395 pre-
dominated in period 1 (1991–1994), but ST1464 (an SLV 
of ST271) predominated in periods 4 and 5 (2001–2006). 
Association of ST with Antimicrobial Drug 
Susceptibility and mef/erm Prevalence
Antimicrobial drug susceptibilities were tested for 126 
of 171 serogroup 19 isolates. Degrees of resistance to peni-
cillin and cefotaxime differed among isolates containing 
different STs. In addition, a distinct correlation was found 
between mef/erm prevalence and STs (Table 2). All CC271 
isolates (n = 116, 16 different STs) were not susceptible 
to penicillin and cefotaxime and showed multidrug resis-
tance to >3 antimicrobial drug classes. Erythromycin MICs 
of CC271 isolates were >256 μg/mL and were all positive 
for mef and erm. However, 5 singlets that were unrelated to 
CC271 showed different patterns of antimicrobial drug sus-
ceptibility and presence of mef/erm determinants (Table 2). 
Four serotype 19A isolates representing ST1374 appeared 
to be less resistant to 2 β-lactam antimicrobial drugs than 
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Table 1. Distributions of serotypes among 538 isolates from children in South Korea, by age group, 1991–2006* 
No. (%) invasive isolates†  No. (%) noninvasive isolates† 
Serotype  <24 mo  24–59 mo  >60 mo  Total <24 mo  24–59 mo  >60 mo  Total
PCV7 serotypes  44 (67)  28 (68)  24 (47)  96 (61)  113 (65)  81 (71)  42 (45)  236 (62) 
  19F  8 (12)  6 (15)  4 (8)  18 (11) 50 (29)  33 (29)  12 (13)  95 (25) 
  23F  16 (24)  6 (15)  4 (8)  26 (16)  32 (18)  20 (18)  18 (19)  70 (18) 
  6B  8 (12)  3 (7)  7 (14)  18 (11)  19 (11)  10 (9)  3 (3)  32 (8) 
  14  7 (11)  10 (24)  5 (10)  22 (14)  8 (5)  7 (6)  3 (3)  18 (5) 
  9V  4 (6)  3 (7)  3 (6)  10 (6)  4 (2)  8 (7)  2 (2)  14 (4) 
  4  0 (0)  0 (0)  0 (0)  0 (0)  0 (0)  2 (2)  4 (4)  6 (2) 
  18C  1 (2)  0 (0)  1 (2)  2 (1)  0 (0)  1 (1)  0 (0)  1 (0) 
PCV7-related serotypes  3 (5)  6 (15)  7 (14)  16 (10)  15 (9)  14 (12)  9 (9)  38 (10) 
  6A  3 (5)  5 (12)  6 (12)  14 (9)  12 (7)  10 (9)  7 (7)  29 (8) 
  23A  0 (0)  1 (2)  1 (2)  2 (1)  3 (2)  4 (4)  0 (0)  7 (2) 
  9N  0 (0)  0 (0)  0 (0)  0 (0)  0 (0)  0 (0)  2 (2)  2 (1) 
19A 11 (16)  2 (5)  0 (0)  13 (8)  27 (16)  8 (7)  10 (11)  45 (12) 
Non-PCV7 serotypes  8 (12)  5 (12)  20 (39) 33 (21)‡  18 (11)  11 (10)  32 (35)  61 (16) 
Total 66 (100)  41 (100)  51 (100)  158 (100)  173 (100)  114 (100)  93 (100)  380 (100) 
*PVC7, 7-valent conjugate vaccine. 
†Percentages have been rounded. 
‡Thirteen serogroups were included among 33 invasive isolates as follows: 15 (6 strains), 24F (6), 10 (4), 34 (3), 35 (3), 1 (2), 3 (2), 12F (2), 5 (1), 11A 
(1), 13 (1), 20 (1), and 27 (1). RESEARCH
CC271 isolates. ST 1374 strains were also highly resistant 
to erythromycin (MIC >256 μg/mL) and were positive 
for ermB only. Strains of ST2394, ST2395, and ST2399 
showed a lower degree of erythromycin resistance (MIC = 
2–8 μg/mL) than CC271 and ST1374 and contained mefA 
only. One serotype, 19F strain of ST1203, did not express 
mef or erm. Serotypes 19A and 19F strains with CC271 
were shown to be closely related to the internationally es-
tablished clone, Taiwan19F-14, which is multidrug resistant 
and carries mefA/ermB macrolide–resistance determinants 
deﬁ  ned by the pneumococcal molecular epidemiology net-
work (22).
Discussion
We found that before PCV7 introduction in South 
Korea, the proportion of serotype 19A isolates increased 
from 0% in 1991 to 26% in 2003 but 19F isolates decreased 
during the same period. Our study also demonstrated that 
multidrug-resistant ST320 isolates containing mef/erm de-
terminants were responsible for the expansion of serotype 
19A.  
In the United States, serotype 19A is now the most im-
portant cause of IPD by replacement serotypes (4,8,23,24). 
Contrary to what we report for South Korea, the increase in 
the United States was documented after widespread use of 
PCV7 (4–6). Increase in non-PCV7 serotypes, i.e., serotype 
replacement, has been noted in carriage studies and the pre-
licensure clinical trials (11,25,26). After widespread use 
of PCV7 in young children, replacement of serotypes for 
IPD has been described for several serotypes in previous 
studies (4–6). Of these, an increase in the incidence of IPD 
cases caused by serotype 19A was quite high. Therefore, 
the increasing prevalence of IPDs caused by serotype 19A 
among the vaccine target group is of considerable concern. 
Our ﬁ  ndings of an increase in serotype 19A disease before 
conjugate vaccine introduction calls into question the role 
vaccine may play in the emergence of serotype 19A disease 
and suggests that other factors are important.
Of the factors contributing to the increase in serotype 
19A, the MLST ﬁ  ndings in our study point to a homoge-
neous pattern of ST320. ST320 of serotype 19A might have 
originated from ST271 or ST236 strains that have been 
prevalent among serotype 19F since 1993 (20) or could 
have been introduced from other countries. Thus, single 
clonal expansion of ST320, related to a multidrug-resistant 
internationally prevalent clone, Taiwan19F-14 (that also car-
ries mefA/ermB determinants), was most likely responsible 
for the prevaccine increase observed for serotype 19A. An-
timicrobial drug use may provide selective pressure that 
would give this highly resistant strain an advantage over 
other strains. A study in the United States demonstrated 
an increasing prevalence of mefA/ermB; 17% percent of 
221 children had been colonized by mefA/ermB contain-
ing serogroup 19 pneumococci strains after receiving at 
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Figure 1. Distribution of serotypes with regard to 7-valent conjugate 
vaccine (PCV7) among 538 isolates encountered during ﬁ  ve 3-year 
periods from 1991 through 2006, South Korea. A) Invasive isolates. 
B) Noninvasive isolates.
Figure 2. Distribution of serotypes with 
regard to 7-valent conjugate vaccine 
(PCV7) among 107 pneumococci 
isolated from children <5 years of 
age with an invasive pneumococcal 
infection (IPD) during ﬁ   ve 3- or 4-
year periods from 1991 through 2006, 
South Korea. *The observed increase 
in the proportion of 19A (p = 0.005) 
and decrease in the proportion of 19F 
(p = 0.008) among invasive isolates 
were statistically signiﬁ  cant.Streptococcus pneumoniae Serotype 19A in Children
least 1 dose of PCV7; the major clonal type was related to 
Taiwan19F-14 (27). In Alaska, the increase observed in 19A 
colonization and IPD seems to be related to CC172 clonal 
expansion (8). In contrast, recent genetic analysis of 19A 
strains isolated after PCV7 use in the United States showed 
that diverse mechanisms were involved in the expansion of 
19A strains, expansion of preexisting predominant CC199, 
capsular switching of PCV7 types (4, 6, 14, and 9V), and 
appearance of multiple unrelated multidrug-resistant CCs 
among serotype 19A strains (CC271, including ST1451 
and ST320, CC156, and CC1296) (4). Capsular switching 
of PCV7 serotypes under selective pressure by vaccine use 
is one of the mechanisms underlying the expansion of se-
rotype 19A (4,11–13,28). However, there is no evidence of 
capsular switching as a contributing factor to the increase 
in serotype 19A in our study. 
We also found that serotype 19F gradually decreased 
in proportion and diversiﬁ  ed to include several newer de-
scendants that differ from the founder by only 1 or 2 of 7 
alleles but ST320 was not a major genetic structure among 
serotype 19F strains (18). Thus, it appears that ST320 has 
a selective advantage in serotype 19A strains, whereas 
ST320 did not seem to have expansion merit in the close 
serotype 19F strains. This ﬁ  nding suggests that the proper-
ties of particular clonal or capsular types are likely impor-
tant determining factors of the potential of pneumococci to 
inﬂ  uence disease type and severity (29,30). Further studies 
are necessary to explain why certain sequence types exhibit 
different selective pressures according to serotype, even for 
close serotypes such as 19A and 19F. 
This study has several limitations. First, pneumococcal 
isolates were collected at a single center, and thus, may not 
represent the national situation. However, no surveillance 
system has been established for IPD in South Korea. Nev-
ertheless, at least 2 studies have demonstrated a recent in-
crease in serotype 19A isolates among children in daycare 
centers (3% in 2002 and 11% in 2004) (14,31). In addi-
tion, the number of serotype 19A isolates from children and 
adults at another tertiary South Korean hospital showed an 
increase over the same period (32). Second, the number of 
19A isolates was relatively small, and it is possible that un-
common strains possessing minor clones were not detected. 
Thus, our ﬁ  nding of a clonal expansion of ST320 among 
serotype 19A strains may be an overstatement. However, 
MLST analysis showed that all 7 of the 19A strains from 
colonized children who were identiﬁ  ed from a previous 
study (14) were of ST320 (H.J. Lee, unpub. data).
The present study has implications for future pneu-
mococcal immunization programs. In particular, the dem-
onstration of an increase in 19A before the use of PCV7 
suggests that PCV7 vaccination may not be entirely respon-
sible for the observed increase of serotype 19A. Had the 
vaccine been introduced in 2000, as in the United States, 
the increase of serotype 19A would have been attributed 
to serotype replacement after PCV7 introduction. Never-
theless, whether minor multidrug-resistant clones of sero-
type 19A (appearing after the introduction of PCV7 in the 
United States) possess an advantage to increase with time 
is a concern (23,29). 
We demonstrated that multidrug-resistant ST320 
strains among serotype 19A have selective advantage in 
terms of expansion over ST1374, which were less resistant 
to β-lactams in a country where antimicrobial drug thera-
py is frequently used. Reports on PCV7 efﬁ  cacy indicate 
negligible cross-protection for serotype 19A (11). In addi-
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Figure 3. Relationship of 126 strains of serogroup 19 by eBURST 
analysis. ST271 (blue circle) is the predicted primary founder 
and ST236 (yellow circle) was assigned to a subgroup founder. 
Numbers on the diagram correspond to sequence types (STs). The 
size of each circle correlates with the number of isolates of that ST. 
*Newly identiﬁ  ed ST in this study. 
Figure 4. Distributions of sequence types (STs) of serotypes 19A 
and 19F during ﬁ  ve 3-or 4-year periods from 1991 through 2006, 
South Korea. *Indicates 11 different STs that contained 1 isolate of 
serotype 19F. A) Invasive isolates. B) Noninvasive isolates.RESEARCH
tion, a recent increase in the antimicrobial drug resistance 
of invasive 19A isolates and the increase in colonization 
by serogroup 19 strains carrying mef/erm determinants 
raise the possibility of potential increases in the prevalence 
of this clone. Thus, potential for colonization because of 
widespread antimicrobial drug use and resistance may in-
teract and provide the selective advantage necessary for 
serotype expansion, which may be the situation in South 
Korea. Similarly, the inﬂ  uence of population characteristic 
dynamics, i.e., HIV infection or poverty and overcrowd-
ing, as well as PCV7 introduction, may combine with the 
necessary factor for serotype replacement and play an im-
portant role in serotype expansion, which may be the situ-
ation in Alaska. It is too early to determine the effect of 
PCV7 on expansion of serotype 19A in South Korea. PCV7 
was introduced in South Korea in November 2003 when 
PCV7 serotype coverage was 56% among invasive isolates 
in children <5 years of age. In 2007, PCV7 coverage is 
≈30% of the target group (21). At this time it is difﬁ  cult to 
predict the effect of low vaccination coverage on serotype 
expansion/replacement. Therefore, surveillance is essential 
to monitor antimicrobial drug resistance, serotype expan-
sion, and serotype replacement as early indications of an 
increase in pneumococcal disease by non-PCV7 or PCV7-
related serotypes.  
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